462 related articles for article (PubMed ID: 32046074)
1. Inflammatory Targets in Diabetic Nephropathy.
Donate-Correa J; Luis-Rodríguez D; Martín-Núñez E; Tagua VG; Hernández-Carballo C; Ferri C; Rodríguez-Rodríguez AE; Mora-Fernández C; Navarro-González JF
J Clin Med; 2020 Feb; 9(2):. PubMed ID: 32046074
[TBL] [Abstract][Full Text] [Related]
2. Inflammatory Cytokines in Diabetic Kidney Disease: Pathophysiologic and Therapeutic Implications.
Donate-Correa J; Ferri CM; Sánchez-Quintana F; Pérez-Castro A; González-Luis A; Martín-Núñez E; Mora-Fernández C; Navarro-González JF
Front Med (Lausanne); 2020; 7():628289. PubMed ID: 33553221
[TBL] [Abstract][Full Text] [Related]
3. MicroRNAs as Regulators of Immune and Inflammatory Responses: Potential Therapeutic Targets in Diabetic Nephropathy.
Zhou H; Ni WJ; Meng XM; Tang LQ
Front Cell Dev Biol; 2020; 8():618536. PubMed ID: 33569382
[TBL] [Abstract][Full Text] [Related]
4. The Role of Endoplasmic Reticulum Stress in Diabetic Nephropathy.
Fan Y; Lee K; Wang N; He JC
Curr Diab Rep; 2017 Mar; 17(3):17. PubMed ID: 28271468
[TBL] [Abstract][Full Text] [Related]
5. Management of diabetic nephropathy: Recent progress and future perspective.
Ahmad J
Diabetes Metab Syndr; 2015; 9(4):343-58. PubMed ID: 25845297
[TBL] [Abstract][Full Text] [Related]
6. The analysis of risk factors for diabetic nephropathy progression and the construction of a prognostic database for chronic kidney diseases.
Wang G; Ouyang J; Li S; Wang H; Lian B; Liu Z; Xie L
J Transl Med; 2019 Aug; 17(1):264. PubMed ID: 31409386
[TBL] [Abstract][Full Text] [Related]
7. Key pathways in renal disease progression of experimental diabetes.
Zoja C; Zanchi C; Benigni A
Nephrol Dial Transplant; 2015 Aug; 30 Suppl 4():iv54-9. PubMed ID: 26209738
[TBL] [Abstract][Full Text] [Related]
8. Proteomics in diabetic nephropathy.
Kim HJ; Yoo HS; Kim CW
Proteomics Clin Appl; 2008 Mar; 2(3):301-11. PubMed ID: 21136835
[TBL] [Abstract][Full Text] [Related]
9. Role of heparanase-driven inflammatory cascade in pathogenesis of diabetic nephropathy.
Goldberg R; Rubinstein AM; Gil N; Hermano E; Li JP; van der Vlag J; Atzmon R; Meirovitz A; Elkin M
Diabetes; 2014 Dec; 63(12):4302-13. PubMed ID: 25008182
[TBL] [Abstract][Full Text] [Related]
10. Cytokines in diabetic nephropathy.
Wu CC; Sytwu HK; Lin YF
Adv Clin Chem; 2012; 56():55-74. PubMed ID: 22397028
[TBL] [Abstract][Full Text] [Related]
11. Targeting inflammation in diabetic nephropathy: a tale of hope.
Moreno JA; Gomez-Guerrero C; Mas S; Sanz AB; Lorenzo O; Ruiz-Ortega M; Opazo L; Mezzano S; Egido J
Expert Opin Investig Drugs; 2018 Nov; 27(11):917-930. PubMed ID: 30334635
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic insight of diabetic nephropathy and its pharmacotherapeutic targets: An update.
Bhattacharjee N; Barma S; Konwar N; Dewanjee S; Manna P
Eur J Pharmacol; 2016 Nov; 791():8-24. PubMed ID: 27568833
[TBL] [Abstract][Full Text] [Related]
13. Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy.
Elmarakby AA; Sullivan JC
Cardiovasc Ther; 2012 Feb; 30(1):49-59. PubMed ID: 20718759
[TBL] [Abstract][Full Text] [Related]
14. Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes.
De Nicola L; Gabbai FB; Liberti ME; Sagliocca A; Conte G; Minutolo R
Am J Kidney Dis; 2014 Jul; 64(1):16-24. PubMed ID: 24673844
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-17A blockade reduces albuminuria and kidney injury in an accelerated model of diabetic nephropathy.
Lavoz C; Matus YS; Orejudo M; Carpio JD; Droguett A; Egido J; Mezzano S; Ruiz-Ortega M
Kidney Int; 2019 Jun; 95(6):1418-1432. PubMed ID: 30982673
[TBL] [Abstract][Full Text] [Related]
16. Lessons learned from studies of the natural history of diabetic nephropathy in young type 1 diabetic patients.
Steinke JM; Mauer M;
Pediatr Endocrinol Rev; 2008 Aug; 5 Suppl 4():958-63. PubMed ID: 18806710
[TBL] [Abstract][Full Text] [Related]
17. The role of non-coding RNAs in diabetic nephropathy: potential applications as biomarkers for disease development and progression.
Alvarez ML; Distefano JK
Diabetes Res Clin Pract; 2013 Jan; 99(1):1-11. PubMed ID: 23102915
[TBL] [Abstract][Full Text] [Related]
18. The Inhibitory Effect of Rapamycin on Toll Like Receptor 4 and Interleukin 17 in the Early Stage of Rat Diabetic Nephropathy.
Yu R; Bo H; Villani V; Spencer PJ; Fu P
Kidney Blood Press Res; 2016; 41(1):55-69. PubMed ID: 26849067
[TBL] [Abstract][Full Text] [Related]
19. Renal iron accelerates the progression of diabetic nephropathy in the HFE gene knockout mouse model of iron overload.
Chaudhary K; Chilakala A; Ananth S; Mandala A; Veeranan-Karmegam R; Powell FL; Ganapathy V; Gnana-Prakasam JP
Am J Physiol Renal Physiol; 2019 Aug; 317(2):F512-F517. PubMed ID: 31188032
[TBL] [Abstract][Full Text] [Related]
20. Novel insights into the pathophysiology and clinical aspects of diabetic nephropathy.
Ilyas Z; Chaiban JT; Krikorian A
Rev Endocr Metab Disord; 2017 Mar; 18(1):21-28. PubMed ID: 28289965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
